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1The recognition that adipose tissue is an endocrine organ raised new prospects for discovering adipose-derived 
products that could be valuable drug targets for the treatment 
and prevention of cardiometabolic diseases. In this context, 
adiponectin, a 30 kDa protein largely produced by mature 
adipocytes, has been attracting widespread attention because 
of insulin-sensitizing, anti-inflammatory, antiatherogenic, and 
cardiomyocyte-protective properties demonstrated in animal 
models.1
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However, human studies have yielded a far more com-
plicated picture. Unlike most other adipokines, circulating 
adiponectin concentration is higher with lower adiposity.2 In 
prospective observational studies in humans using multivari-
able regression, higher circulating adiponectin is associated 
with lower risk of type 2 diabetes mellitus,3 hepatic dysfunc-
tion,4 and metabolic syndrome5 but higher mortality in patients 
with kidney disease, heart failure, previous cardiovascular dis-
ease, or general elderly cohorts6–9; this different direction of 
effect between risk of incident disease and mortality among 
high-risk groups has been called the adiponectin paradox.10
Given the complex metabolic derangements that might 
participate in and compensatory changes that might occur in 
response to human diseases, the association between adiponectin 
concentration and cardiometabolic biomarkers and disease end 
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points might be explained by reverse causality (where disease 
status could alter adiponectin concentration) or residual con-
founding (where adiponectin could be a marker of another causal 
factor, such as adiposity or insulin resistance).11 Classical multi-
variable regression studies cannot distinguish causal from non-
causal associations, and randomized controlled trials specifically 
targeting adiponectin are not possible in the absence of a specific 
therapeutic targeting adiponectin concentration or function.
Mendelian randomization uses genetic variants (mostly 
single-nucleotide polymorphisms [SNPs]) that are robustly 
related to the risk factor of interest as tools to assess its role 
in causing disease.12 The random allocation of parental alleles 
at meiosis should theoretically reduce confounding in genetic 
association studies, and this has been shown to be the case13; 
the unidirectional flow of biological information from genetic 
variant to phenotypes avoids reverse causality. Mendelian ran-
domization has been used in clinical research to investigate 
potential etiologic mechanisms, such as the causal effects of 
low-density lipoprotein cholesterol (LDL-C),14 systolic blood 
pressure,15 and CRP (C-reactive protein)16 on coronary heart 
disease, validate and prioritize novel drug targets, such as IL-6 
(interleukin-6) receptor,17 and increase understanding of cur-
rent therapies, for example, statins.18
Previous Mendelian randomization studies indicate that cir-
culating adiponectin is a consequence of low insulin sensitivity,19 
but whether adiponectin concentration is also a cause of insulin 
sensitivity is uncertain.19–21 Using Mendelian randomization in a 
study of 63 746 coronary heart disease cases and 130 681 con-
trols, we have recently shown that adiponectin may not be caus-
ally related to coronary heart disease.22 Although multivariable 
analyses show that higher adiponectin concentration is associ-
ated with lower glycated hemoglobin, insulin, triglycerides 
(TG), and higher high-density lipoprotein cholesterol (HDL-C), 
using Mendelian randomization, we found little evidence that 
these were causal.22 Whether adiponectin is associated with 
systemic metabolic profile, and, if it is, what aspects of these 
associations are causal is unknown. A broader interrogation of 
the metabolic effects of adiponectin through high-throughput 
profiling of metabolic status could provide valuable insights into 
whether adiponectin is a noncausal biomarker or causally impor-
tant in the pathophysiology of some human diseases.23
We combined genotype, adiponectin, and metabolomics 
profile data from 6 longitudinal studies and 1 genome-wide 
association consortium with the aim of (1) defining the met-
abolic signature of blood adiponectin concentration and (2) 
investigating whether variation in adiponectin concentration is 
causally related to the systemic metabolic profile.
Methods
Study Populations
The metabolic profile associated with blood adiponectin concentration 
was examined from 7 data sources: PEL82 (the 1982 Pelotas Birth 
Cohort), including adults aged 30 years old born in the city of Pelotas, 
Brazil, in 198224,25; BWHHS (the British Women’s Heart and Health 
Study), including UK women aged 60 to 79 years old at recruitment 
in 200026; WHII study (the Whitehall II), including UK government 
workers aged 45 to 69 years at phase 5 clinical assessment in 1997 to 
199927; the CaPS (Caerphilly Prospective Study), including men aged 
52 to 72 years at phase III in 1989 to 199328; a case–control study nest-
ed in UKCTOCS (the United Kingdom Collaborative Trial of Ovarian 
Cancer Screening), including UK postmenopausal women aged 50 to 
74 years at recruitment in 2001 to 200529; the ALSPAC-M (Cohort of 
Mothers From the Avon Longitudinal Study of Children and Parents), 
including UK women aged 34 to 63 years old at clinical assessment 
in 2009 to 201130; and a metabolomics genome-wide association con-
sortium (hereafter referred to as Metabolomics consortium), including 
European adults with mean age of 45 years old from 14 cohorts.31 
Individual-level data were available to investigators from PEL82, 
BWHHS, WHII, CaPS, UKCTOCS, and ALSPAC-M. Individual-level 
study data cannot be made available to other researchers for purposes 
of reproducing the results or replicating the procedure. Summary-level 
data are publicly available from the Metabolomics consortium (URL: 
http://www.computationalmedicine.fi/data/NMR_GWAS/).
All study participants provided written informed consent, and 
study protocols were approved by the local ethics committees (ethi-
cal approval for ALSPAC was also obtained from the ALSPAC Ethics 
and Law Committee). Studies’ characteristics are summarized in 
Table 1. We examined (possibly causal) associations of adiponectin 
with systemic metabolic profiles using 2 approaches—conventional 
multivariable regression and Mendelian randomization analyses. 
Studies must have both adiponectin and measures of some of the out-
comes (but do not need genetic data) to contribute to multivariable 
regression analyses and must have relevant genetic variants and out-
comes (but do not need adiponectin concentration data) to contribute 
to Mendelian randomization analyses. Figure 1 shows how the differ-
ent data sources contributed to the 2 approaches.
Metabolite Quantification
A high-throughput serum nuclear magnetic resonance (NMR) spec-
troscopy platform was used to quantify ≤150 metabolic measures and 
83 derived measures (ratios) in each study. The experimental proto-
cols, including sample preparation and NMR spectroscopy methods, 
have been described in detail elsewhere32,33 and are described brief-
ly in Methods in the Data Supplement. Sixty-six of 150 metabolic 
measures were selected for this study aimed at broadly representing 
the systemic metabolite profile, as previously reported by Würtz 
et al,34 including lipoprotein traits (lipid content, particle size, and 
Apo [apolipoproteins]), fatty acids, amino acids, glycolysis-related 
metabolites, ketone bodies, fluid balance (albumin and creatinine), 
and inflammatory markers (glycoprotein acetyls). The remaining 84 
metabolic measures from the NMR platform are related to other lipid 
fractions (esterified and free cholesterol, total cholesterol, TG, and 
phospholipids) and particle concentration from 14 lipoprotein sub-
classes. As these 84 metabolic measures are highly correlated with ≥1 
of the 66 selected metabolic measures, they were not included in the 
main analysis (as they would not bring additional information) and 
were presented in the Data Supplement. Eight additional measures, 
not obtained from the NMR platform, were included: CRP, IL-6, fi-
brinogen, blood viscosity, insulin, glycated hemoglobin, and systolic 
blood pressure and diastolic blood pressure. PEL82 did not have data 
on metabolic measures from NMR platform and contributed data to 
analyses of conventional lipid risk factors (total cholesterol, HDL-C, 
LDL-C, and TG) and some of the additional measures described 
(CRP, glycated hemoglobin, systolic blood pressure, and diastolic 
blood pressure). Adiponectin was assayed using an ELISA in PEL82, 
BWHHS, and WHII. Data on adiponectin level were not available 
from CaPS, UKCTOCS, ALSPAC-M, and the Metabolomics con-
sortium. Blood samples used for adiponectin, NMR metabolites, 
and other blood-based outcomes assays were taken after overnight 
or minimum 6-hour fast in BWHHS, CaPS, and ALSPAC-M and on 
nonfasting samples in PEL82 and UKCTOCS. In WHII, participants 
attending the morning clinic were asked to fast overnight and those 
attending in the afternoon were asked to have a light, fat-free break-
fast before 08:00 hours. The vast majority of samples contributing to 
the Metabolomics consortium were fasting samples.
Genotyping
BWHHS, CaPS, WHII, and UKCTOCS participants were genotyped us-
ing Metabochip, a platform comprising 200 000 SNPs, which cover the 
loci identified by genome-wide association studies in cardiometabolic 
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diseases and rare variants from the 1000 Genomes Project.35 Quality 
control criteria and imputation using 1000 Genomes European ances-
try reference samples have been previously described for studies within 
UCLEB consortium (University College London, London School of 
Hygiene & Tropical Medicine, University of Edinburgh and University 
of Bristol).36 In ALSPAC-M, 557 124 SNPs were directly genotyped us-
ing Illumina human660W quad. For quality control, SNPs were exclud-
ed if missingness >5%, Hardy–Weinberg equilibrium P value <1×10−6, 
or minor allele frequency <1%, and samples were excluded if missing-
ness >5%, indeterminate X chromosome heterozygosity, extreme auto-
somal heterozygosity, or showing evidence of population stratification. 
Imputation was performed using 1000 genomes reference panel (Phase 
1, Version 3; phased using ShapeIt v2.r644, haplotype release date 
December 2013) and Impute V2.2.2. For PEL82, genotyping was per-
formed by using the Illumina HumanOmni2.5-8v1 array (Illumina Inc), 
and ≈2 500 000 SNPs were genotyped.37 For PEL82, quality control cri-
teria have been previously described,37 and imputation was performed in 
2 steps: first, genotypes were phased using SHAPEIT; then, IMPUTE2 
was used for the actual imputation. For autosomal and X chromosome 
SNPs, 1000 Genomes Phase I integrated haplotypes (December 2013 
release) and 1000 Genomes Phase I integrated variant set (March 2012 
release), respectively, were used. For PEL82, ancestry-informative 
principal components were based on 370 539 SNPs shared by samples 
from the HapMap Project, the Human Genome Diversity Project, and 
PEL82.38 Cohorts contributing to the Metabolomics consortium used 
different SNP arrays; nongenotyped SNPs were imputed using a 1000 
Genomes Project March 2012 version and SNPs with accurate imputa-
tion (proper info >0.4) and minor allele count >3 were combined in 
fixed-effects meta-analysis using double genomic control correction. 
Further details can be found in the consortium publication.31
Other Covariates
Anthropometric variables (weight and height) were measured in each 
study using standard procedures, and body mass index was calculated 
as weight (kg)/height (m)2. Demographic and smoking status infor-
mation was obtained through questionnaires.
Data Analysis
Before multivariable and genetic analyses, each study adjusted meta-
bolic measures for age, sex, and, if applicable, place of recruitment 
(BWHHS and UKCTOCS) or principal components of genomic ances-
try (PEL82 and some studies contributing to Metabolomics consortium), 
and the resulting residuals were transformed to normal distribution and 
standardized using inverse rank-based normal transformation. Pregnant 
women from PEL82 (n=73) and ALSPAC-M (n=12) were excluded. 
As the 74 analyzed metabolic measures are highly correlated, we ad-
opted a similar strategy to the Metabolomics consortium31 to correct 
for multiple testing by estimating the number of independent tests as 
the number of principal components that explained over 95% of vari-
ance in metabolic measures using data from the 2 studies (BWHHS 
and WHII) with the largest available number of metabolites (n=27 prin-
cipal components in both studies). As a result, for both multivariable 
and Mendelian randomization analyses, we corrected for multiple 
testing using the Bonferroni method considering 27 independent tests 
(P=0.05/27≈0.0019). Analyses were conducted in Stata version 12.
Multivariable Regression Analysis
The conventional multivariable regression association of adiponec-
tin with individual metabolites was estimated using a 2-stage indi-
vidual participant meta-analysis. In the first stage, linear regression 
models were fitted for each study. In the second stage, study-specific 
estimates were meta-analyzed using DerSimonian and Laird random-
effect model.39 Heterogeneity across studies was assessed using I2 (as 
a measure of the relative size of between-study variation and within-
study error).40 Three types of subgroup analyses were conducted: sex-
stratified analysis, analysis excluding individuals with high risk of 
cardiometabolic disease (those that had experienced coronary artery 
disease or stroke or those older than 65 years), and analysis restricted 
to European studies (excluding PEL82).
Genetic Analyses
Four independent SNPs in the vicinity of ADIPOQ locus (±50 
kb), previously identified to predict adiponectin levels, were se-
lected22,41 (details in Methods in the Data Supplement). These SNPs 
(rs6810075, rs16861209, rs17366568, and rs3774261) are estimated 
to explain ≈4% of variance in adiponectin concentration (details in 
Methods in the Data Supplement). Data for the association of each 
selected SNP with adiponectin concentration in the discovery sample 
of ADIPOGen, the largest consortium of genome-wide association 
studies for adiponectin, were downloaded from https://www.mcgill.
ca/genepi/adipogen-consortium.
Association of Genetic Variants With Classical Confounders
The association between genetic variants and classical con-
founders (sex, age, ancestry [European versus non-European], 
current smoking [yes versus no], and body mass index) was 
examined for each study that provided individual-level data 
using logistic or linear regression models for binary or con-
tinuous variables, respectively.
Mendelian Randomization Analysis
To allow all participants with relevant genetic and metabolic 
measure data to contribute to analyses, even when adiponectin 
data were not available (as in CaPS, UKCTOCS, ALSPAC-M, 
and Metabolomics consortium), a 2-sample Mendelian ran-
domization design was used, in which data for the association 
between genetic variants and adiponectin levels were obtained 
from an external data source, the ADIPOGen consortium.42 The 
2-sample Mendelian randomization is a recent extension to the 
Figure 1. Schematic representation of studies contributing to 
each analytic approach. From the available data sources, 3 had 
data on adiponectin and metabolic measures and could contrib-
ute to multivariable analysis (PEL82 [1982 Pelotas Birth Cohort], 
BWHHS [British Women’s Heart and Health Study], and WHII 
study [Whitehall II]), and all had data on genetic variants and 
metabolic measures and could contribute to Mendelian random-
ization analysis (PEL82, BWHHS, WHII, CaPS [the Caerphilly Pro-
spective Study], UKCTOCS [the United Kingdom Collaborative 
Trial of Ovarian Cancer Screening], ALSPAC-M [Cohort of Moth-
ers From the Avon Longitudinal Study of Children and Parents], 
and Metabolomics consortium).
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more conventional 1-sample Mendelian randomization and, 
when samples are independent, has the additional advantage of 
avoiding bias because of genetic variants correlating with con-
founders by chance (statistical overfitting).43 The 2-sample Men-
delian randomization estimates and respective SEs were obtained 
by combining SNP-specific Wald ratios, as described by Burgess 
et al44 and detailed in Methods in the Data Supplement. Study-
specific Mendelian randomization estimates were meta-analyzed 
using DerSimonian and Laird random-effect model.39 Heteroge-
neity across studies was assessed using I2.40 Subgroup analyses 
were conducted considering individual-level (sex and risk of car-
diometabolic disease) and study-level characteristics (European 
versus non-European studies). The Metabolomics consortium did 
not contribute to subgroup analysis of individual-level charac-
teristics as only summary data were available.
Comparison Between Multivariable and Mendelian 
Randomization Analyses
Results from conventional multivariable and Mendelian randomiza-
tion analyses for each metabolic measure were compared using the Z 
test (details in the Methods in the Data Supplement) and by estimat-
ing the correlation between multivariable and Mendelian randomiza-
tion estimates across all metabolic measures. Power calculations for 
multivariable and Mendelian randomization analysis are available in 
Table I in the Data Supplement.
Results
The study included a median sample size of 3008 adults in 
the multivariable analysis (range: 2470–5909) and a median 
sample size of 29 146 adults in the Mendelian randomization 
analysis (range: 4647–37 545). Total sample size for each 
metabolite in multivariable and Mendelian randomization 
analysis can be found in Table II in the Data Supplement. 
Characteristics of participants and distribution of metabolites 
from each contributing study are listed in Table 2 and Table III 
in the Data Supplement.
Adiponectin and the Systemic Metabolic Profile
In the multivariable analysis, adiponectin was associated with 
59 of 74 (80%) metabolites at nominal level (P<0.05) and 49 
of 74 (66%) after correcting for multiple testing (P<0.0019). 
Overall, higher circulating adiponectin was associated with a 
healthier systemic metabolite profile. Blood adiponectin con-
centration was strongly related to multiple lipoprotein traits. 
With higher adiponectin concentration, lipid concentration 
was lower in very low-density lipoprotein (VLDL) subclasses 
and higher in HDL subclasses, except for small HDL. There 
was no strong evidence of circulating adiponectin associating 
with total lipid content in LDL subclasses or in intermediate-
density lipoprotein, although adiponectin concentration was 
inversely associated with LDL-TG. Higher adiponectin was 
associated with lower concentration of cholesterol, TG, and 
lower mean particle diameter in VLDL, as well as higher cho-
lesterol concentration and mean particle diameter in HDL. 
Higher adiponectin concentration was also associated with 
higher concentration of Apo AI and phospholipids and lower 
concentration of TG and diglycerides (Figure 2).
Higher circulating adiponectin was also associated with 
healthier glycemic status (lower glucose and insulin concentra-
tion), lower blood concentration of glycolysis-related metab-
olites (lactate and pyruvate), saturated fatty acids, systemic 
inflammatory markers (CRP, fibrinogen, IL-6, glycoprotein 
Table 2. Characteristics of Studies’ Populations
 PEL82 BWHHS WHII CaPS UKCTOCS ALSPAC-M
Metabolomics 
Consortium
%
  Male 49 0 72 100 0 0 45
  White 75 100 93 100 97 97 NA*
  Smoker 24 12 17 20 NA 11 NA
  Overweight/obese 58 72 57 69 60 56 NA
Median (p25, p75)
  Age, y 30 (30, 30) 69 (64, 73) 55 (51, 61) 56 (53, 60) 66 (60, 70) 48 (45, 51) 45 (24, 61)†
  Adiponectin, µg/mL 7.9 (5.2, 11.9) 15.8 (10.8, 21.5) 8.5 (6.1, 12) NA NA NA NA
  Glucose, mmol/L 4.8 (4.4, 5.3) 4.7 (4.3, 5.1) 5 (4.7, 5.4) 3.8 (3.5, 4.2) 2.2 (1.7, 3.1) 4.4 (4.1, 4.7) NA
  HDL-C, mmol/L 1.5 (1.2, 1.7) 1.6 (1.4, 1.9) 1.5 (1.3, 1.7) 0.9 (0.7, 1) 1.6 (1.4, 1.9) 1.7 (1.5, 1.9) NA
  LDL-C, mmol/L 2.7 (2.3, 3.3) 2.3 (1.9, 2.8) 1.9 (1.6, 2.2) 1.6 (1.3, 1.9) 1.8 (1.4, 2.2) 1.5 (1.2, 1.8) NA
TG, mmol/L 1.1 (0.8, 1.6) 1.5 (1.1, 2) 1.1 (0.9, 1.5) 1.5 (1.2, 2) 1.5 (1.1, 2.1) 0.9 (0.7, 1.2) NA
SBP, mm Hg 120 (112, 130) 146 (130, 163) 121 (111, 133) 144 (130, 160) NA 117 (110, 125) NA
DBP, mm Hg 75 (69, 81) 79 (71, 87) 77 (70, 84) 84 (76, 92) NA 71 (66, 77) NA
ALSPAC-M indicates the Avon Longitudinal Study of Children and Parents-Mothers’ Cohort; BWHHS, British Women’s Heart and Health Study; CaPS, the Caerphilly 
Prospective Study; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NA: not available; PEL82, 
1982 Pelotas Birth Cohort; SBP, systolic blood pressure; TG, triglycerides; UKCTOCS, Case–Control Study Nested in the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening; and WHII study, Whitehall II.
*Cohorts contributing to the Metabolomics consortium were of European origin.
†Overall mean age (and range of mean age across studies).
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acetyls, and blood viscosity), blood pressure, creatinine, and 
higher ketone bodies (acetoacetate). In addition, higher adipo-
nectin concentration was associated with lower concentrations 
of free branched-chain amino acids (isoleucine, leucine, and 
valine), aromatic amino acids (phenylalanine and tyrosine), 
and alanine and higher concentration of glutamine (Figure 3).
In the multivariable analyses, evidence of heterogeneity 
in pooled estimates across studies was substantial (I2=50%–
75%) for 12 and high (I2>75%) for 15 metabolic measures 
(Figures 2 and 3; Tables IVA and V in the Data Supplement). 
This did not seem to be accounted by sex (Figures I through IV 
in the Data Supplement), geographic location (Figures V and 
VI in the Data Supplement), or high risk of disease (Figures 
VII and VIII in the Data Supplement). Results were consistent 
for metabolites not included in the main analysis (Figures IX 
and X in the Data Supplement).
Causal Effects of Adiponectin on the Systemic 
Metabolic Profile
Characteristics of the 4 SNPs (rs6810075, rs16861209, 
rs17366568, and rs3774261) used in Mendelian randomiza-
tion and their association with adiponectin concentration are 
Figure 2. Association of lipoprotein traits with blood adiponectin levels from multivariable and Mendelian randomization (MR) analysis. 
Values are expressed as units of standardized metabolite concentration (and 95% CI [confidence interval]) per 1 U increment of standard-
ized log adiponectin levels. P values for the association between adiponectin and metabolites are indicated by *** if lower than Bonferroni-
adjusted threshold (P value <0.0019). Heterogeneity was considered substantial if I2=50% to 75% (+) or high if I2>75% (++). P values for the 
comparison between multivariable and MR estimates are displayed in the column MR vs MV (P value). Metabolic measures were adjusted 
for age, sex, and, if applicable, place of recruitment (BWHHS [British Women’s Heart and Health Study] and UKCTOCS [the United King-
dom Collaborative Trial of Ovarian Cancer Screening]) or principal components of genomic ancestry (PEL82 [1982 Pelotas Birth Cohort] 
and some studies contributing to Metabolomics consortium), and the resulting residuals were transformed to normal distribution by inverse 
rank-based normal transformation. A indicates the Avon Longitudinal Study of Children and Parents-Mothers’ Cohort; Apo, apolipoprotein; 
B, BWHHS; C, the Caerphilly Prospective Study; DAG, diglycerides; HDL, high-density lipoprotein; HDL-C, HDL cholesterol; HDLd, HDL 
particle mean diameter; IDL, intermediate-density lipoprotein; L-HDL, large HDL; L-LDL, large LDL; L-VLDL, large VLDL; LDL, low-density 
lipoprotein; LDL-C, LDL cholesterol; LDLd, LDL particle mean diameter; M-HDL, medium HDL; M-LDL, medium LDL; M-VLDL, medium 
VLDL; M, Metabolomics consortium; P, PEL82; S-HDL, small HDL; S-LDL, small LDL; S-VLDL, small VLDL; TG, triglycerides; U, UKCTOCS 
Nested Case–Control Study; VLDL, very-low-density lipoprotein; VLDL-C, VLDL cholesterol; VLDLd, VLDL particle mean diameter; W, 
Whitehall II Study; XL-HDL, very large HDL; XL-VLDL, very large VLDL; XS-VLDL, very small VLDL; and XXL-VLDL, extremely large VLDL.
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shown in Table 3. Overall, SNPs effect allele frequency was 
similar across studies. Two SNPs had lower allele frequency 
in the Metabolomics consortium (rs6810075: 51% versus 
65%–69% in other studies; rs16861209: 5% versus 9%–11% 
in other studies), and 1 SNP had a higher frequency in PEL82 
compared with other studies (rs3774261: 49% versus 38%–
39% in other studies; Table 3). As expected, the selected SNPs 
were not associated with classical confounders overall (Table 
VI in the Data Supplement).
Findings from Mendelian randomization analysis were 
largely inconsistent with results from multivariable analysis. 
First, there was no evidence that adiponectin influenced HDL 
and VLDL traits (Figure 2). Second, genetically increased adi-
ponectin levels were not associated with glycemic traits, free 
Figure 3. Association of multiple metabolic measures with blood adiponectin levels from multivariable and Mendelian randomization (MR) 
analysis. Values are expressed as units of standardized metabolite concentration (and 95% CI [confidence interval]) per 1 U increment of 
standardized log adiponectin levels. P values for the association between adiponectin and metabolites are indicated by *** if lower than 
Bonferroni-adjusted threshold (P value <0.0019). Heterogeneity was considered substantial if I2=50% to 75% (+) or high if I2>75% (++). P 
values for the comparison between multivariable and MR estimates are displayed in the column MR vs MV (P value). Metabolic measures 
were adjusted for age, sex, and, if applicable, place of recruitment (BWHHS [British Women’s Heart and Health Study] and UKCTOCS [the 
United Kingdom Collaborative Trial of Ovarian Cancer Screening]) or principal components of genomic ancestry (PEL82 [1982 Pelotas 
Birth Cohort] and some studies contributing to Metabolomics consortium) and the resulting residuals were transformed to normal distri-
bution by inverse rank-based normal transformation. A indicates the Avon Longitudinal Study of Children and Parents-Mothers’ Cohort; 
B, BWHHS; C, the Caerphilly Prospective Study; CLA, conjugated linoleic acids; CRP, C-reactive protein; DBP, diastolic blood pressure; 
DHA, docosahexaenoic acid; FAw3, omega-3 fatty acid; FAw6, omega-6 fatty acid; GlycA, glycoprotein acetyls; HbA1c, glycated hemo-
globin; IL-6, interleukin-6; LA, linoleic acid; M, Metabolomics consortium; MUFA, monounsaturated fatty acid; P, PEL82; PUFA, polyun-
saturated fatty acids; SBP, systolic blood pressure; SFA, saturated fatty acid; TotFA, total fatty acids; U, UKCTOCS Nested Case–Control 
Study, and W, Whitehall II Study.
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amino acids, and glycolysis-related metabolites (Figure 3). 
Results were less conclusive for some inflammatory mark-
ers (IL-6 and fibrinogen; Figure 3). Third, there was strong 
statistical evidence that associations from multivariable and 
Mendelian randomization analyses were inconsistent with 
each other (Figures 2 and 3), and the overall correlation 
between multivariable and Mendelian randomization esti-
mates was low (r=0.10; Figure 4). Finally, in the Mendelian 
randomization analysis, adiponectin was not associated with 
any of the metabolic measures at either P <0.05 or P <0.0019.
In the Mendelian randomization analyses, evidence of het-
erogeneity in pooled estimates across studies was substantial 
(I2=50%–75%) for 14 and high (I2>75%) for 3 metabolic mea-
sures, suggesting lower heterogeneity in models from genetic 
analysis than from the multivariable analyses (Figures 2 and 3; 
Tables IVB and V in the Data Supplement). This did not seem 
to be driven by sex differences (Figures I through IV in the Data 
Supplement), geographic location/ethnicity (Figures V and VI in 
the Data Supplement), or high risk of disease (Figures VII and 
VIII in the Data Supplement). Results were consistent with no 
association between adiponectin and metabolites not included 
in the main analysis (Figures IX and X in the Data Supplement).
Discussion
In ≤5909 adults, we found using multivariable regression 
analyses that circulating adiponectin was associated with a 
pattern of systemic metabolites levels associated with good 
health. Higher blood adiponectin concentration was associated 
with higher HDL lipids and lower VLDL lipids, glycemia, and 
branched-chain amino acids levels. However, when we used 
genetic variants in the vicinity of adiponectin-encoding gene 
to test the causal effect of adiponectin on systemic metabolic 
profiles among ≤37 545 adults, we found little evidence that 
the associations were causal.
Genetic association studies indicate that genetic variants 
associated with circulating adiponectin (in loci other than 
ADIPOQ) are also associated with cardiometabolic outcomes, 
such as type 2 diabetes mellitus42 and coronary heart disease41; 
however, this is likely to be reflecting a pleiotropic effect of 
these variants. Our findings and previous Mendelian random-
ization studies19,22 suggest that the association between circulat-
ing adiponectin and metabolic biomarkers and cardiometabolic 
diseases is likely to be explained by shared factors (confound-
ing) rather than by a direct role of adiponectin on metabolism 
and downstream cardiometabolic disease. These results are in 
contrast to findings from animal models pointing to insulin-
sensitizing and antiatherogenic actions of adiponectin.1
Circulating adiponectin is known to be substantially 
reduced among obese individuals, particularly in the presence 
of central fat accumulation.45 A recent Mendelian randomiza-
tion study examining the causal metabolic effects of body mass 
index demonstrated that lower body mass index was related 
to favorable lipoprotein subclass profile and lower concentra-
tion of branched-chain amino acids, inflammatory markers, 
and insulin,34 which is remarkably similar to our results from 
the conventional multivariable analysis. In addition, numer-
ous studies have shown that adiponectin production is sup-
pressed by insulin action in humans, which seems to be at least 
partly attributed to regulation at the transcriptional level.46 As 
Table 3. Characteristics of SNPs Selected for Mendelian 
Randomization Analysis
 
SNP
rs6810075 rs16861209 rs17366568 rs3774261
Chr 3 3 3 3
Position* 186548565 186563114 186570453 186571559
Closest gene ADIPOQ ADIPOQ ADIPOQ-AS1, 
ADIPOQ
ADIPOQ-AS1, 
ADIPOQ
EA T A G A
NEA C C A G
ADIPOGen consortium
  EAF† 0.63 0.07 0.90 0.39
  β 0.11 0.31 0.25 0.11
  SE 0.01 0.02 0.01 0.01
PEL82
  EAF 0.65 0.11 0.92 0.49
  β 0.13 0.33 0.22 0.08
  SE 0.03 0.04 0.05 0.03
  R2 0.008 0.021 0.005 0.002
BWHHS
  EAF 0.67 0.09 0.89 0.38
  β 0.32 0.30 1.04 0.30
  SE 0.10 0.14 0.24 0.08
R2 0.022 0.020 0.051 0.044
WHII
  EAF 0.68 0.10 0.89 0.38
  β 0.16 0.36 0.56 0.14
  SE 0.04 0.05 0.08 0.03
  R2 0.008 0.027 0.025 0.010
CaPS§
  EAF 0.69 0.10 0.89 0.39
UKCTOCS§
  EAF 0.69 0.10 0.89 0.38
ALSPAC-M§
  EAF 0.66 0.09 0.93 0.38
Metabolomics consortium§
  EAF 0.51 0.05 0.88 0.36
β (and SE) refers to mean difference in standardized log adiponectin per 
additional SNP effect allele.   ALSPAC-M indicates the Avon Longitudinal Study 
of Children and Parents-Mothers’ Cohort; BWHHS, British Women’s Heart and 
Health Study; CaPS, the Caerphilly Prospective Study; Chr, chromosome; EA, 
effect allele; EAF, effect allele frequency; NEA, noneffect allele; PEL82, 1982 
Pelotas Birth Cohort; SNP, single-nucleotide polymorphism; UKCTOCS, case–
control study nested in the United Kingdom Collaborative Trial of Ovarian Cancer 
Screening; and WHII study, Whitehall II.
*Genome Reference Consortium Human Build 37.
§For CaPS, UKCTOCS, ALSPAC-M, and the Metabolomics consortium, data 
on adiponectin levels were not available.
†Extracted from Dastani et al (2012).42
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an example, elevated circulating adiponectin is found in con-
texts of both primary deficiency of insulin (type 1 diabetes 
mellitus)47 and global insulin resistance because of genetic or 
acquired defects in the insulin receptor.48 Genetic predisposition 
to insulin resistance and central fat accumulation45,49 is related 
to lower circulating adiponectin. Evidence from animal models 
has raised the possibility of a bidirectional relationship between 
adiponectin and insulin concentration.50 Early Mendelian ran-
domization studies did indicate that adiponectin could mitigate 
insulin resistance20,21; however, these results could not be repli-
cated in a larger Mendelian randomization study,19 as well as in 
our study presented here. The well-known metabolic effects of 
adiposity and insulin on circulating adiponectin concentration 
reinforce that the clustering of adiponectin and several tradi-
tional and novel biomarkers is likely to result from confounding 
because of increasing adiposity and disruption of insulin action.
Strengths of our study include detailed metabolic profile 
in several longitudinal studies, which enabled us to charac-
terize the metabolic profile of high adiponectin concentration 
beyond traditional biomarkers, as well as the use of Mendelian 
randomization to disentangle the causal effect of adiponectin 
on the metabolism. Mendelian randomization analysis can 
reliably test for the presence of a causal relation under the 3 
assumptions of an instrumental variable that the genetic vari-
ants (1) are robustly associated with the risk factor of interest 
(adiponectin), (2) should only affect the outcome (metabolites) 
through the exposure, and (3) are not associated with exposure–
outcome confounders.51 To ensure that the instrumental vari-
able assumptions were met, or were at least plausible, we only 
used SNPs strongly and specifically (within ADIPOQ gene) 
related to adiponectin concentration as instrumental variables 
and we adjusted for population structure in models using data 
from PEL82 to avoid confounding by population stratification. 
One of the limitations of our study was the limited power in 
subgroup analyses including only individual-level data (sex- 
and risk-stratified analyses), which limited our investigation 
of potential sources of heterogeneity. Another limitation was 
the absence of data on high–molecular weight adiponectin, 
which is believed to account for most of the adiponectin bio-
logical effects in experimental settings. However, most human 
Figure 4. Correlation between estimates from multivariable regression and Mendelian randomization (MR). Apo indicates apolipopro-
tein; CLA, conjugated linoleic acids, CRP, C-reactive protein; DAG, diglycerides; DBP, diastolic blood pressure; DHA, docosahexaenoic 
acid; FAw3, omega-3 fatty acid; FAw6, omega-6 fatty acid; GlycA, glycoprotein acetyls; HbA1c, glycated hemoglobin; HDL, high-density 
lipoprotein; HDL-C, HDL cholesterol; HDLd, HDL particle mean diameter; IDL, intermediate-density lipoprotein; IDL-C, IDL cholesterol; 
IL-6, interleukin-6; L-HDL, large HDL; L-LDL, large LDL; L-VLDL, large VLDL; LA, linoleic acid; LDL, low-density lipoprotein; LDL-C, LDL 
cholesterol; LDLd, LDL particle mean diameter M-HDL, medium HDL; M-LDL, medium LDL; M-VLDL, medium VLDL; MUFA, monounsat-
urated fatty acid; r, Pearson correlation coefficient; S-HDL, small HDL; S-LDL, small LDL; S-VLDL, small VLDL; SBP, systolic blood pres-
sure; SFA, saturated fatty acid; TG, triglycerides; VLDL, very-low-density lipoprotein; VLDL-C, VLDL cholesterol; VLDLd, VLDL particle 
mean diameter; XL-HDL, very large HDL; XL-VLDL, very large VLDL; XS-VLDL, very small VLDL; and XXL-VLDL, extremely large VLDL.
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(and many animal model) studies have not used high–molecu-
lar weight adiponectin, and we found the same multivariable 
observational associations as in previous studies. Also, it should 
be emphasized that SNPs in ADIPOQ gene are associated with 
both total and high–molecular weight adiponectin,52–54 includ-
ing SNPs we used in our analysis (eg, rs3774261)52 or others 
in high linkage disequilibrium with these (eg, rs16861209 is 
highly correlated with rs17300539 − R2 >0.8).53,54
Overall, our findings suggest that low circulating adipo-
nectin is likely to reflect adipocyte dysfunction and that altered 
total blood adiponectin concentration is an epiphenomenon in 
the context of metabolic disease, rather than a key determinant. 
Therefore, interventions targeting manipulation of adiponec-
tin concentration are unlikely to result in therapeutic benefits 
for tackling cardiometabolic diseases. Our results highlight the 
potential of Mendelian randomization analysis and high-through-
put metabolomics profiling to yield important insights to advance 
our understanding in the pathophysiology of common complex 
diseases and to inform which targets are best bets for taking for-
ward into drug development, given that drug target validation 
is a key obstacle underlying the unsustainably high rate of drug 
development failure. Although our and other studies suggest that 
adiponectin is not a valuable target for developing drugs aimed 
at preventing cardiometabolic diseases, it may nonetheless be a 
valuable biomarker for predicting these diseases given the wide-
ranging associations shown here. The associations we have found 
would need to be replicated in additional independent studies 
before testing their ability to predict disease outcomes.
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CLINICAL PERSPECTIVE
Adiponectin, a protein produced by adipose cells, has insulin-sensitizing, anti-inflammatory, antiatherogenic, and cardio-
myocyte-protective properties in animal models. In prospective studies in humans, higher circulating adiponectin is asso-
ciated with lower risk of type 2 diabetes mellitus, hepatic dysfunction, and metabolic syndrome. However, it is not clear 
whether adiponectin is protective against these metabolic disorders or whether these associations are just reflecting reverse 
causality (where disease status could alter adiponectin concentration) or residual confounding (where adiponectin could 
be a marker of another causal factor, such as adiposity or insulin resistance). We used Mendelian randomization to clarify 
whether circulating adiponectin is causally related to the metabolic profile of ≤37 545 adults. Four common genetic vari-
ants nearby the gene encoding adiponectin (ADIPOQ) were used as instruments to test the effect of circulating adiponectin 
on 74 metabolic measures selected to broadly represent the systemic metabolite profile, including lipoprotein subclasses, 
fatty acids, glycemic traits, free amino acids, inflammatory markers, and blood pressure. Overall, our findings do not sup-
port a direct role of circulating adiponectin on the systemic metabolic profile in humans and indicate that the clustering of 
adiponectin and several traditional and novel biomarkers is likely to result from confounding or reverse causality. Therefore, 
interventions targeting manipulation of adiponectin concentration are unlikely to result in therapeutic benefits for tackling 
metabolic diseases.
